Today: 5 June 2026
AMD stock ticks up as CEO Lisa Su lines up a $26.7 million share sale
12 February 2026
2 mins read

AMD stock ticks up as CEO Lisa Su lines up a $26.7 million share sale

New York, Feb 12, 2026, 10:45 (EST) — Regular session

  • AMD edged up roughly 0.2% after a new filing revealed CEO Lisa Su intends to sell as many as 125,000 shares.
  • AMD’s Forrest Norrod signaled plans to unload 19,450 shares, according to a separate Form 144 filing.
  • Looking ahead: Friday brings inflation data, with Nvidia set to report earnings Feb. 25, and AMD taking a conference slot March 3.

Advanced Micro Devices (AMD) ticked up 0.2% to $214.06 in Thursday morning trading after a regulatory filing disclosed that CEO Lisa Su intends to sell as many as 125,000 shares. The Form 144, which is required for certain executive trades under SEC Rule 144, put the value of the planned sale at roughly $26.7 million. According to the notice, the transaction would run through Morgan Stanley Smith Barney on a 10b5-1 plan set up back on Sept. 9. The filing also referenced a 125,000-share sale in December and a 40,000-share donation to Fidelity Charitable. Nvidia added about 0.9%, while Intel slipped 0.4%.

Form 144s don’t usually make waves. But when a stock turns into an AI hardware play and the previous earnings round has investors on edge, those filings start grabbing attention.

AMD wants a solid hold on the No. 2 spot for data-center AI accelerators and systems, sitting just behind Nvidia. That puts the stock in the spotlight—every fresh data point, even the most mundane, tends to pull in attention.

On Wednesday, a separate Form 144 revealed AMD officer Forrest E. Norrod is set to sell as many as 19,450 shares—worth roughly $4.2 million—via Morgan Stanley Smith Barney. The filing cited a 10b5-1 plan put in place on June 6, 2025, and also disclosed an identical-sized sale last November.

AMD closed Wednesday unchanged at $213.58, holding steady after a 1.1% decline the day before, price data showed. Shares moved between roughly $209 and $220 across those two sessions.

Form 144 just signals a possible sale—there’s no guarantee of an actual trade. 10b5-1 plans, on the other hand, can quietly execute sales over an extended period. Still, when insiders look to sell, extra shares entering the market can keep traders on edge, especially if the stock is still looking for its footing after a downturn.

The turbulence landed in early February. AMD dropped 13% on Feb. 4, rattled by a cautious sales forecast that rekindled worries over its lag behind Nvidia in AI. Stacy Rasgon at Bernstein called the results barely more than “inline”—if you set aside China—and pointed out that short-term AI figures “are not really inflecting.” Reuters

Wild moves lately underscore just how tough it is for AI hardware stocks to impress. “The expectations for large blowout quarters for AI-related hardware companies have skewed what the market is looking for,” said Bob O’Donnell, president of TECHnalysis Research. Reuters

Traders are eyeing weekly jobless claims and existing home sales data set for release later Thursday. Friday brings an inflation report that might shake up rate outlooks.

Nvidia’s results are due Feb. 25, and the Street wants clues on AI chip demand and how spending is shaping up in the broader space. As for AMD, it’s set to speak at the Morgan Stanley Technology, Media & Telecom conference March 3.

AMD’s immediate hurdles: inflation numbers land Friday, then Nvidia’s Feb. 25 report could either jolt or sap momentum across the AI chip space. Eyes turn next to the March 3 conference for any new commentary from the company.

Stock Market Today

  • MoonLake Immunotherapeutics CFO Sells Small Stake Under Prearranged Plan, No Investor Alarm
    June 4, 2026, 10:41 PM EDT. MoonLake Immunotherapeutics (MLTX) CFO Matthias Bodenstedt sold 13,653 shares, about 1.1% of his holdings, in a Rule 10b5-1 trading plan on May 11, 2026. This plan allows insiders to sell shares on a preset schedule to avoid allegations of insider trading. Bodenstedt retains over 1.17 million shares, valued at $22 million post-transaction. The sale is smaller than his April 2026 disposition and involves no derivative holdings. MoonLake, a clinical-stage biotech developing sonelokimab for inflammatory diseases, faces a 63% share price drop over the past year but remains a high-risk, potentially high-reward stock with positive drug trial results. Analysts largely rate it a Buy despite the firm's pre-revenue status and significant net losses.

Latest articles

Dow Hits Record, But Wall Street Watches After-Hours Session

Dow Hits Record, But Wall Street Watches After-Hours Session

5 June 2026
Dow soared to a record close, but after-hours jitters hit as Broadcom missed revenue expectations and cut its AI-chip forecast, dragging chip stocks and exposing markets to Friday’s key jobs report, which could sway rates, yields, and tech valuations. Lululemon shares plunged 11% after slashing its profit outlook.
AT&T Stock Drops, Investors Eye SpaceX’s Move

AT&T Stock Drops, Investors Eye SpaceX’s Move

5 June 2026
AT&T shares plunged 3.3% to $22.77 after a Supreme Court loss and an Oppenheimer downgrade citing rising satellite broadband competition, as SpaceX’s $75 billion IPO nears; investors fear AT&T’s fiber-heavy strategy faces new risks, with Oppenheimer warning broadband and mobile growth could be at risk from low Earth orbit rivals.
Marvell rises as chip peers drop, Wall Street eyes index move

Marvell rises as chip peers drop, Wall Street eyes index move

5 June 2026
Marvell jumped 4.9% to $316.43, defying a chip selloff, as traders bet on S&P 500 inclusion and Nvidia-linked AI demand; the stock later slipped to $305.18 after hours, with volume more than double average, as investors await Friday’s S&P announcement and weigh risks of high expectations and index flows.
Guidewire Beats Earnings but Shares Drop on Revenue Number

Guidewire Beats Earnings but Shares Drop on Revenue Number

5 June 2026
Guidewire Software plunged 13.77% after hours to $130.36 as investors fixated on annual recurring revenue guidance that missed Wall Street’s target by a narrow margin, overshadowing strong earnings and revenue beats; the stock’s sharp drop highlights concerns over contract growth pacing despite raised full-year outlooks and robust financials.
Advanced Energy Industries (AEIS) stock rises again after earnings — what traders watch next
Previous Story

Advanced Energy Industries (AEIS) stock rises again after earnings — what traders watch next

Oracle stock slips despite $88 million U.S. Air Force cloud win as investors brace for CPI
Next Story

Oracle stock slips despite $88 million U.S. Air Force cloud win as investors brace for CPI

Go toTop